Dimerix Stock

Dimerix P/B

The P/B (Price-to-Book Ratio) of Dimerix (DXB.AX) as of Jul 16, 2026 is 22.21. In the previous year, P/B (Price-to-Book Ratio) was 16.34 — a change of 35.92% (higher).

P/B

22.21

YoY

35.92%

Last updated:

P/B (Price-to-Book Ratio) of Dimerix is 2026 22.21 . P/B (Price-to-Book Ratio) of Dimerix was 2025 16.34 . It decreases by 35.92% higher compared to the previous year.
Access this data via the Eulerpool API

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

P/B (Price-to-Book Ratio) of Dimerix is 22.21 in 2026.

Access this data via the Eulerpool API

Valuation — Dimerix

All Key Metrics — Dimerix